James I. Dunlop
Research Subjects
James I. Dunlop has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alain Kohl
Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Departments of Tropical Disease Biology and Vector Biology, Liverpool L3 5QA, United Kingdom
1 shared publication - Andrew T. Clarke
MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
1 shared publication - Arvind H. Patel
University of Glasgow
1 shared publication - Benjamin Brennan
MRC-University of Glasgow Centre for Virus Research
1 shared publication - Benjamin G. Davis
The Rosalind Franklin Institute
1 shared publication - Brian James Willett
MRC-University of Glasgow Centre for Virus Research
1 shared publication
Latest Publications
- Open Access
- 16 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Live-cell 3D-SIM of Rift Valley fever virus NSs filaments reveals a polygon web architecture
A defining feature of Rift Valley fever virus (RVFV) is the incorporation of the NSs protein into large filamentous assemblies inside infected nuclei [R. Swanepoel, N. K. Blackburn, J. Gen. Virol. 34 , 557–561 (1977).], as judged from fixed specimens. To gain insight into the 3D structure of NSs filaments within live-cell nuclei, we used genetic-code expansion (GCE) to incorporate trans-cyclooct-2-en-L-lysine into the protein. This enabled site-specific fluorescent labeling with tetrazine dyes for live-cell structured illumination microscopy (SIM). Our superresolved images revealed the complete native architecture of NSs filaments as a micron-scale polygon web of fibers with discrete domain characteristics, overturning previous assumptions of simple linear filaments. Parallel experiments on fixed RVFV-infected cells confirmed that native NSs filaments also display this morphology. Overall, our 3D-SIM analysis reveals distinct structural plasticity within NSs filaments, establishing a quantitative structure–function relationship that support the importance of polygon organization for NSs filament function during RVFV infection.
- 16 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Open AccessLive-cell 3D-SIM of Rift Valley fever virus NSs filaments reveals a polygon web architecture
A defining feature of Rift Valley fever virus (RVFV) is the incorporation of the NSs protein into large filamentous assemblies inside infected nuclei [R. Swanepoel, N. K. Blackburn, J. Gen. Virol. 34 , 557–561 (1977).], as judged from fixed specimens. To gain insight into the 3D structure of NSs filaments within live-cell nuclei, we used genetic-code expansion (GCE) to incorporate trans-cyclooct-2-en-L-lysine into the protein. This enabled site-specific fluorescent labeling with tetrazine dyes for live-cell structured illumination microscopy (SIM). Our superresolved images revealed the complete native architecture of NSs filaments as a micron-scale polygon web of fibers with discrete domain characteristics, overturning previous assumptions of simple linear filaments. Parallel experiments on fixed RVFV-infected cells confirmed that native NSs filaments also display this morphology. Overall, our 3D-SIM analysis reveals distinct structural plasticity within NSs filaments, establishing a quantitative structure–function relationship that support the importance of polygon organization for NSs filament function during RVFV infection.
- Open Access
- 10 March 2022
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 1 (1) , pgac024
Exploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model
Dabie bandavirus (previously severe fever with thrombocytopenia syndrome virus; SFTSV), is an emerging tick-borne bunyavirus responsible for severe fever with thrombocytopenia syndrome (SFTS), a disease with high case fatality that is characterized by high fever, thrombocytopenia, and potentially lethal hemorrhagic manifestations. Currently, neither effective therapeutic strategies nor approved vaccines exist for SFTS. Therefore, there remains a pressing need to better understand the pathogenesis of the disease and to identify therapeutic strategies to ameliorate SFTS outcomes. Using a type I interferon (IFN)-deficient mouse model, we investigated the viral tropism, disease kinetics, and the role of the virulence factor nonstructural protein (NSs) in SFTS. Ly6C+ MHCII+ cells in the lymphatic tissues were identified as an important target cell for SFTSV. Advanced SFTS was characterized by significant migration of inflammatory leukocytes, notably neutrophils, into the lymph node and spleen, however, these cells were not required to orchestrate the disease phenotype. The development of SFTS was associated with significant upregulation of proinflammatory cytokines, including high levels of IFN-γ and IL-6 in the serum, lymph node, and spleen. Humoral immunity generated by inoculation with delNSs SFTSV was 100% protective. Importantly, NSs was critical to the inhibition of the host IFNɣ response or downstream IFN-stimulated gene production and allowed for the establishment of severe disease. Finally, therapeutic but not prophylactic use of anti-IL-6 antibodies significantly increased the survival of mice following SFTSV infection and, therefore, this treatment modality presents a novel therapeutic strategy for treating severe SFTS.
- 10 March 2022
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 1 (1) , pgac024
Open AccessExploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model
Dabie bandavirus (previously severe fever with thrombocytopenia syndrome virus; SFTSV), is an emerging tick-borne bunyavirus responsible for severe fever with thrombocytopenia syndrome (SFTS), a disease with high case fatality that is characterized by high fever, thrombocytopenia, and potentially lethal hemorrhagic manifestations. Currently, neither effective therapeutic strategies nor approved vaccines exist for SFTS. Therefore, there remains a pressing need to better understand the pathogenesis of the disease and to identify therapeutic strategies to ameliorate SFTS outcomes. Using a type I interferon (IFN)-deficient mouse model, we investigated the viral tropism, disease kinetics, and the role of the virulence factor nonstructural protein (NSs) in SFTS. Ly6C+ MHCII+ cells in the lymphatic tissues were identified as an important target cell for SFTSV. Advanced SFTS was characterized by significant migration of inflammatory leukocytes, notably neutrophils, into the lymph node and spleen, however, these cells were not required to orchestrate the disease phenotype. The development of SFTS was associated with significant upregulation of proinflammatory cytokines, including high levels of IFN-γ and IL-6 in the serum, lymph node, and spleen. Humoral immunity generated by inoculation with delNSs SFTSV was 100% protective. Importantly, NSs was critical to the inhibition of the host IFNɣ response or downstream IFN-stimulated gene production and allowed for the establishment of severe disease. Finally, therapeutic but not prophylactic use of anti-IL-6 antibodies significantly increased the survival of mice following SFTSV infection and, therefore, this treatment modality presents a novel therapeutic strategy for treating severe SFTS.